AIMT News and Press, Aimmune Therapeutics Inc. From 04/17/20

On March 16, Aimmune Therapeutics (NASDAQ: AIMT) announced that the first patients in the U.S. had begun treatment with its recently approved immunotherapy for peanut allergies, Palforzia. On the same day, investors learned that the U.S. Food and Drug Administration (FDA) had questions ...

For parents, having a child with peanut allergies come into accidental contact with the protein, via unlabeled foods at a potluck event, birthday party, or school lunch can be devastating. The results range in severity, from minor skin reactions to life-threatening anaphylaxis. It's an...

The Food and Drug Administration (FDA) made numerous drug approval decisions in the first quarter. These binary events can cause stock prices to skyrocket or plummet depending on the outcome. Here we explore four companies that successfully attained FDA approval. It marked the first drug ever...

Introduction At the end of 2019 I wrote an article highlighting the reasons why I felt DBV Technologies (NASDAQ: DBVT ) was substantially undervalued. At the time DBVT was trading for around $9, subsequently climbed to $13.49 by mid-January, and then nosedived to a low of $2.02. The s...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the 19 th Annual Needham Virtual Healthcare Conf...

Aimmune (AIMT) has been on my 2019 watch list, but the stock's premium price prevented me from committing to a buy. Now, the recent sell-off has AIMT near the top of my shopping list. The company is in the process of launching their first FDA-approved product, Palforzia, for the mitigation of ...

Osmotica Pharmaceuticals (NASDAQ: OSMT ) initiated with Buy rating and $8 (74% upside) price target at SunTrust. More news on: Osmotica Pharmaceuticals plc, Epizyme, Inc., Baxter International Inc., Healthcare stocks news, Stocks on the move, , Read more ...

AcelRx Pharmaceuticals Reports Q4 Results, to Acquire Tetraphase Pharmaceuticals AcelRx ( ACRX ) reported its fourth quarter and full-year results while also announcing its plan to acquire Tetraphase Pharmaceuticals (TTPH). The company ended the year with $66.1 million in cash, cash equiva...

DBV Technologies (NASDAQ: DBVT ) craters  45%  premarket on increased volume in reaction to its announcement that the FDA, during its review of its marketing application for Viaskin Peanut, has identified "questions" about efficacy, including the impact of patch-site adhesion. ...

Aimmune Therapeutics (NASDAQ: AIMT ) announces that the first patients in the U.S. are being treated with PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, St...